General Information - The company is named Shenzhen Huitai Medical Equipment Co., Ltd. and was established through the overall change of Shenzhen Huitai Medical Equipment Co., Ltd. [2] - The company was registered with a capital of RMB 141,013,796 and is a permanent corporation [2][3] - The company was approved for listing on the Shanghai Stock Exchange's Sci-Tech Innovation Board on September 8, 2020, and officially listed on January 7, 2021, with an initial public offering of 16.67 million shares [2] Business Objectives and Scope - The company's business objective is to focus on independent innovation and development in the field of vascular minimally invasive intervention, contributing significantly to global healthcare [2] - The business scope includes the production, operation, and leasing of various classes of medical devices, as well as technology services and development [2] Share Structure - The total number of shares issued by the company is 141,013,796, all of which are ordinary shares [3] - The company’s shares are issued in the form of stocks, and each share of the same category has equal rights [3][4] Shareholder Rights and Responsibilities - Shareholders have the right to participate in shareholder meetings, receive dividends, and request information about the company [5][6] - Shareholders are obligated to comply with laws and regulations, pay for their subscribed shares, and not abuse their rights to harm the company or other shareholders [8][9] Governance Structure - The company is governed by a board of directors, with the chairman serving as the legal representative [2][3] - The company has established an audit committee to oversee compliance and financial integrity [8] Shareholder Meetings - The company holds annual and temporary shareholder meetings, with specific procedures for calling and conducting these meetings [12][13] - Shareholders holding more than 10% of the shares can request the board to convene a temporary meeting [13][14] Financial Management - The company can increase its capital through various methods, including issuing shares to unspecified or specific targets [3][4] - The company is restricted from repurchasing its shares except under certain conditions, such as capital reduction or employee stock ownership plans [3][4] Compliance and Legal Framework - The company adheres to the Company Law and Securities Law of the People's Republic of China, ensuring that all operations are compliant with relevant regulations [2][5] - The company is required to disclose significant transactions and maintain transparency with shareholders [10][11]

证券代码：301370 证券简称：国科恒泰 公告编号：2025-036 国科恒泰（北京）医疗科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 国科恒泰（北京）医疗科技股份有限公司（以下简称"公司"）对资产负债 率超过 70%的单位预计担保金额超过公司最近一期经审计净资产 50%，提请投 资者充分关注担保风险。 本次预计的对外担保事项，系合并报表范围内公司及子公司之间的担保。 一、对外担保情况概述 根据公司经营发展需要，未来十二个月，公司拟向合并报表范围内子公司提 供担保额度总额为 18.55 亿元。其中，为资产负债率 70%以上的合并报表范围内 子公司提供担保的额度为 14.15 亿元；为资产负债率低于 70%的合并报表范围内 子公司提供担保的额度为 4.40 亿元。 上述额度按实际生效的金额（签订担保合同且额度有效期间内存续的担保） 进行总额控制，在担保额度总额范围内，公司子公司间可进行担保额度调剂，但 调剂发生时资产负债率为 70%以上的子公司仅能从股东大会审议时资产负债率 为 70%以上的子公司处获得担保额度。 在担保额度总额 ...